

COVID-19 VACCINE INFORMATION

VACCINE		TRIAL			EFFICACY				VARIANTS	SPECIFICS					ADDITIONAL DOSES		
TYPE	NAME	STATUS (N=PARTICIPANTS)	EUA SUBMISSION	FULL FDA APPROVAL	FIRST DOSE	SECOND DOSE	PEDIATRICS	PREVENTION OF SEVERE DISEASE	OMICRON VARIANTS (BA.4/BA.5)	ADMINISTRATION	DOSES	TIMING	PRODUCTS	STORAGE PREPARATION STABILITY INFORMATION	BIVALENT BOOSTER DOSE (ORIGINAL+BA.4/BA.5)	IMMUNOCOMPROMISED	
MESSENGER RNA (mRNA)	HOW IT WORKS	Pfizer-BioNTech (BNT162b2) (Comirnaty)	Phase 2 & 3 (44,000)	EUA approved for ages 6 months and above	Ages 12 and above	52%	95%	100% Ages 12-17 90.7% Ages 5-11 Comparable to immune response of older participants Ages 6 mo-4 yr	93%	Two Doses: 70% against hospitalization Booster: 85.9%	IM <a href="#">Click for administration instructions</a>	6 months - 4 yo monovalent primary: 3 5 yo - 11 yo Monovalent Primary: 2 Bivalent Booster: 2 (8 weeks apart) 12 yo - 17 yo Monovalent Primary: 2 Bivalent Booster: 2 (8 weeks apart) Adults Monovalent Primary: 2 Bivalent Primary: 2 (8 weeks apart)	Days: 0, 21  Pediatrics (6mo-4yr) Weeks: 0, 3-8, 8	12 yo and older: Gray Vaccine Cap and Label 0.3 mL volume 5 yo - 11 yo Orange Vaccine Cap and Label 0.2 mL volume 6 mo - 4 yo: Maroon Vaccine Cap and Label 0.2 mL volume	<a href="#">Click for Pfizer product information</a>	Updated Boosters: Authorized for a single use booster dose at least two months following primary or booster vaccination. - Moderna: All persons aged ≥6 years may receive a single COVID-19 vaccine booster - Pfizer-BioNTech: All persons aged ≥ 5 years may receive a single COVID-19 vaccine booster - Monovalent mRNA COVID-19 vaccines are not authorized as booster doses for individuals ≥12 years - Only Bivalent mRNA COVID Vaccines are authorized as a booster	<a href="#">See CDC's Recommendations for Primary Series and Booster Doses</a>
VIRAL VECTOR	HOW IT WORKS	Janssen/J&J (Ad26.COV2.S)	Phase 3 (44,325)	FDA limits to certain populations; EUA approved for 18 years and older		67%	94% (booster data)	Safety and efficacy has not been established in individuals younger than 18	77%	85% effectiveness against hospitalization	IM <a href="#">Click for administration instructions</a>	Adult Primary: 1 0.5 mL / Dose  authorized for use in certain limited situations due to safety considerations.	Days: 0	Adult MDV (5 doses)	<a href="#">Click for Janssen Information</a>	All persons 18 and older and vaccinated two or more months ago should receive an updated booster dose of Pfizer-BioNTech or Moderna	<a href="#">See CDC's Recommendations for Primary Series and Booster Doses</a>
PROTEIN SUBUNIT	HOW IT WORKS	Novavax (NVX-CoV2373)	Phase 3 (33,000)	FDA approved emergency use for adults 12 years or older		90.40%	90%	78.3	100%	No studies showing efficacy yet	IM	12 yo and older Monovalent Primary: 2 Bivalent Booster: 2 (8 weeks apart)  mRNA (Moderna, PfizerBioNTech) should be used for the booster dose.	Weeks: 0, 3-8	Adult MDV (10 doses) Vaccine Cap: Royal Blue 0.5 mL volume	<a href="#">Click for NovaVax information</a>	For 12 years and older, an updated booster may be considered 2 months after 2nd dose, can be Pfizer-BioNTech or Moderna  For 18 years and older, a monovalent booster (Novavax) may be considered at least 6 months after completing primary series vaccine and if have not previously or will not receive an updated mRNA booster	<a href="#">See CDC's Recommendations for Primary Series and Booster Doses</a>

**Disclaimer**  
The information contained in this vaccine informational sheet is emerging, rapidly evolving because of ongoing research and events and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of the needs of individual patients. ASHP provides this information to help practitioners better understand the current status of COVID-19 vaccine testing. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised that ASHP is not responsible for the currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information for any purpose. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this vaccine information sheet and will bear no responsibility or liability for the results or consequences of its use.

**ASHP Statement**  
ASHP will continue to advocate on behalf of our members and support COVID-19 vaccine planning efforts; a number of resources are available on our COVID-19 vaccine page.



**Useful Resources**  
[ASHP COVID Vaccine Info Website](#)  
[safemedication.com](#)  
[CDC Booster Shots](#)

Updated 11/16/2022